bictegravir/emtricitabine/tenofovir vs midazolam
PlainMeds reviewed this comparison against our methodology in August 2026. It places FDA and CMS record fields side by side, without recommending either medication.
Side-by-side comparison of bictegravir/emtricitabine/tenofovir and midazolam. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
7.6 Drugs without Clinically Significant Interactions with BIKTARVY Based on drug interaction studies conducted with BIKTARVY or the components of BIKTARVY, no clinically significant drug interactions have been observed when BIKTARVY is combined with the following drugs: ethinyl estradiol, ledipasvir/sofosbuvir, midazolam, norgestimate, sertraline, sofosbuvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir.
Biktarvy
Versed
Biktarvy is a complete HIV-1 treatment for adults and children who weigh at least 31 pounds. It combines three medicines into one tablet to help control the virus.
Midazolam is a medicine that makes you feel calm, relaxed, and sleepy. It can also cause you to forget things that happen while you are taking it.
Biktarvy treats Human Immunodeficiency Virus type 1 (HIV-1) in adults and children weighing at least 31 pounds. It can be used if you have never taken HIV medicine before. It can also replace your current HIV medicine if your virus is under control and you have no resistance to Biktarvy's components.
Midazolam is used to sedate you before a surgery or procedure to help you relax and feel less anxious. It can also be used to help you feel calm during procedures like bronchoscopies or endoscopies. Midazolam can also be used to start general anesthesia before you get other medicines.
Biktarvy contains three drugs that each block HIV in different ways. Bictegravir stops HIV from inserting its DNA into your cells. Emtricitabine and tenofovir alafenamide interfere with an enzyme HIV needs to make copies of itself.
Midazolam belongs to a class of drugs called benzodiazepines. It works by slowing down activity in your brain and nervous system. This helps to reduce anxiety, promote relaxation, and cause sleepiness.
- • Diarrhea
- • Nausea
- • Headache
- • Decreased breathing rate
- • Tenderness at the injection site
- • Pain during injection
No adverse event reports.
- Seizure 1,373
- Hypotension 1,296
- Drug Interaction 1,088
- Toxicity To Various Agents 846
- Acute Kidney Injury 845
If you have both HIV and hepatitis B, stopping Biktarvy can cause your hepatitis B to suddenly get worse. Your doctor will need to monitor your liver closely for several months after you stop taking Biktarvy. You may need to take medicine for hepatitis B.
Midazolam can cause serious breathing problems, including slowed or stopped breathing. This is more likely to happen if you are also taking opioid pain medicines. You must be closely monitored by trained medical staff while receiving midazolam. Make sure the facility has the equipment and medicines needed to treat breathing problems immediately.
There is a pregnancy registry to track outcomes in women who take Biktarvy during pregnancy. Talk to your doctor about the risks and benefits of taking Biktarvy if you are pregnant or planning to become pregnant. There is not enough data to assess the risk of major birth defects.
Tell your doctor if you are pregnant or plan to become pregnant. Midazolam may harm an unborn baby. It is not known if midazolam passes into breast milk. Talk to your doctor about the risks and benefits of using this medicine while breastfeeding.
Also Compare, Nearby Drugs
Compare bictegravir/emtricitabine/tenofovir with
Compare midazolam with
How to Read This bictegravir/emtricitabine/tenofovir vs midazolam Comparison
bictegravir/emtricitabine/tenofovir is classified in the Integrase Inhibitor / NRTI Combination drug class, while midazolam sits within the Benzodiazepine class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, bictegravir/emtricitabine/tenofovir has 0 submissions while midazolam has 5,448. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to clinical studies have shown that these two drugs do not interfere with each other's levels or effectiveness in the body.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for bictegravir/emtricitabine/tenofovir or midazolam.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.